

Jose Luis Diez-martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8076047/publications.pdf>

Version: 2024-02-01

121
papers

2,478
citations

257357

24
h-index

243529

44
g-index

127
all docs

127
docs citations

127
times ranked

3308
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 974-981.	0.5	219
2	Chromosome Studies in 104 Patients With Polycythemia Vera. <i>Mayo Clinic Proceedings</i> , 1991, 66, 287-299.	1.4	138
3	Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. <i>Haematologica</i> , 2017, 102, 401-410.	1.7	109
4	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019, 3, 360-369.	2.5	92
5	Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. <i>Leukemia</i> , 2006, 20, 542-545.	3.3	81
6	Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. <i>Bone Marrow Transplantation</i> , 1998, 21, 133-140.	1.3	77
7	Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. <i>Annals of Hematology</i> , 2010, 89, 1073-1080.	0.8	68
8	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. <i>Journal of Hematology and Oncology</i> , 2020, 13, 46.	6.9	68
9	Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. <i>Haematologica</i> , 2010, 95, 1176-1182.	1.7	63
10	Interobserver variance in myelodysplastic syndromes with less than 5% bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2% blasts. <i>Annals of Hematology</i> , 2015, 94, 565-573.	0.8	62
11	Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). <i>Annals of Oncology</i> , 2014, 25, 1053-1058.	0.6	60
12	Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2014, 93, 239-246.	1.1	60
13	Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. <i>Annals of Internal Medicine</i> , 2018, 169, 674.	2.0	59
14	Evaluation of Minimal Residual Disease by Real-Time Quantitative PCR of Wilms' Tumor 1 Expression in Patients with Acute Myelogenous Leukemia after Allogeneic Stem Cell Transplantation: Correlation with Flow Cytometry and Chimerism. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1235-1242.	2.0	57
15	Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study. <i>HemaSphere</i> , 2021, 5, e538.	1.2	52
16	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 522-528.	2.0	48
17	Possible cytogenetic distinction between lymphoid and myeloid blast crisis in chronic granulocytic leukemia. <i>American Journal of Hematology</i> , 1988, 27, 194-203.	2.0	45
18	A comparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation. <i>Haematologica</i> , 2005, 90, 1373-9.	1.7	43

#	ARTICLE	IF	CITATIONS
19	Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2015-2022.	2.0	42
20	Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. <i>Bone Marrow Transplantation</i> , 2016, 51, 1307-1312.	1.3	31
21	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2766-2775.	3.3	30
22	Unusual presentation of extranodal peripheral T-cell lymphomas with multiple paraneoplastic features. <i>Cancer</i> , 1991, 68, 834-841.	2.0	29
23	Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients with Hematologic Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 143-149.	2.0	28
24	Stem cell mobilization in HIV seropositive patients with lymphoma. <i>Haematologica</i> , 2013, 98, 1762-1768.	1.7	27
25	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2021, 14, 84.	6.9	27
26	Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 349-354.	1.3	25
27	A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. <i>Blood Advances</i> , 2018, 2, 1719-1737.	2.5	25
28	Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. <i>Blood Advances</i> , 2019, 3, 3351-3359.	2.5	25
29	Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. <i>Annals of Hematology</i> , 2021, 100, 541-553.	0.8	25
30	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 422-430.	1.3	24
31	Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. <i>Cancers</i> , 2019, 11, 1364.	1.7	23
32	Donor Cellâ€Derived Hematologic Neoplasms after Hematopoietic Stem Cell Transplantation: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1505-1513.	2.0	22
33	Adult celiac disease, small and medium vessel cutaneous necrotizing vasculitis, and T cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 1988, 19, 973-978.	0.6	20
34	Hematologic disorders in 13 patients with acquired trisomy 21 and 13 individuals with Down syndrome. <i>American Journal of Medical Genetics Part A</i> , 2005, 37, 247-250.	2.4	20
35	Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. <i>Bone Marrow Transplantation</i> , 2017, 52, 1138-1143.	1.3	20
36	Short Tandem Repeats (STRs) as Biomarkers for the Quantitative Follow-Up of Chimerism after Stem Cell Transplantation: Methodological Considerations and Clinical Application. <i>Genes</i> , 2020, 11, 993.	1.0	19

#	ARTICLE	IF	CITATIONS
37	Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. <i>Leukemia</i> , 2011, 25, 880-883.	3.3	18
38	Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 651-658.	2.0	18
39	Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells. <i>Bone Marrow Transplantation</i> , 2014, 49, 212-218.	1.3	17
40	Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. <i>Bone Marrow Transplantation</i> , 2002, 30, 63-68.	1.3	16
41	Graft-Versus-Tumor Effect After Allogeneic Stem Cell Transplantation in HIV-Positive Patients With High-Risk Hematologic Malignancies. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1340-1345.	0.5	16
42	A randomised study of 10µg/kg/day (single dose) vs 2 × 5µg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients. <i>Bone Marrow Transplantation</i> , 2003, 32, 563-567.	1.3	15
43	Lymphoma associated chromosomal abnormalities can easily be detected by FISH on tissue imprints. An underused diagnostic alternative. <i>Journal of Clinical Pathology</i> , 2005, 58, 629-633.	1.0	15
44	A Randomized Controlled Multicenter Study Comparing Recombinant Interleukin 2 (rIL-2) in Conjunction With Recombinant Interferon Alpha (IFN-α) Versus no Immunotherapy for Patients With Malignant Lymphoma Postautologous Stem Cell Transplantation. <i>Journal of Immunotherapy</i> , 2010, 33, 326-333.	1.2	15
45	Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2015, 50, 790-794.	1.3	15
46	Inhibitory killer cell immunoglobulin-like receptor (KIR) mismatches improve survival after T cell repleted haploidentical transplantation. <i>European Journal of Haematology</i> , 2016, 96, 483-491.	1.1	15
47	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , 2019, 125, 90-98.	2.0	15
48	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 936-942.	2.0	15
49	Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide. <i>Hematological Oncology</i> , 2020, 38, 597-603.	0.8	14
50	Rhinocerebral mucormycosis following donor leukocyte infusion: successful treatment with liposomal amphotericin B and surgical debridement. <i>Bone Marrow Transplantation</i> , 1998, 22, 817-818.	1.3	13
51	Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: Experience from a single center. <i>Journal of Clinical Apheresis</i> , 2019, 34, 373-380.	0.7	13
52	Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders. <i>Aids</i> , 2019, 33, 1441-1447.	1.0	13
53	Apparent cure of Graves-Basedow disease after sibling allogeneic bone marrow transplantation. <i>Clinical Endocrinology</i> , 1999, 50, 267-270.	1.2	12
54	Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2010, 21, 1891-1897.	0.6	12

#	ARTICLE	IF	CITATIONS
55	A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis. <i>Medical Mycology</i> , 2020, 58, 300-309.	0.3	12
56	Antithymocyte Globulin-Based Prophylaxis for Graft Versus Host Disease Compared to Post-Transplant Cyclophosphamide-Based Prophylaxis in Matched Unrelated Donor Transplantation. <i>Blood</i> , 2016, 128, 2307-2307.	0.6	12
57	Lineage-specific Chimaerism Quantification after T-cell Depleted Peripheral Blood Stem Cell Transplantation. <i>Leukemia and Lymphoma</i> , 2003, 44, 659-667.	0.6	11
58	The Genotype of the Donor for the (GT) _n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2015, 10, e0140454.	1.1	11
59	Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2018, 101, 332-339.	1.1	11
60	Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2019, 54, 1625-1631.	1.3	11
61	Evolution of the role of haploidentical stem cell transplantation: past, present, and future. <i>Expert Review of Hematology</i> , 2020, 13, 835-850.	1.0	11
62	Successful treatment of incipient graft rejection with donor leukocyte infusions, further proof of a graft versus host lymphohaemopoietic effect. <i>Bone Marrow Transplantation</i> , 2004, 33, 1037-1041.	1.3	10
63	Listeria monocytogenes meningitis in two allogeneic hematopoietic stem cell transplant recipients. <i>Leukemia and Lymphoma</i> , 2006, 47, 1701-1703.	0.6	10
64	Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis. <i>Leukemia</i> , 2018, 32, 1822-1826.	3.3	10
65	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	1.3	10
66	Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant. <i>Frontiers in Immunology</i> , 2021, 12, 674658.	2.2	10
67	Flow cytometric analysis of decay-accelerating factor (CD55) on neutrophils from aplastic anaemia patients. <i>British Journal of Haematology</i> , 1995, 90, 728-730.	1.2	9
68	Hematopoietic Stem Cell Transplantation in Patients Infected With HIV. <i>Current HIV/AIDS Reports</i> , 2010, 7, 175-184.	1.1	9
69	Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 527-535.	0.7	9
70	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 171.e1-171.e8.	0.6	9
71	Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2089-2097.	2.0	8
72	Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021, 127, 2507-2514.	2.0	8

#	ARTICLE	IF	CITATIONS
73	Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility. <i>International Journal of Hematology</i> , 2022, 115, 61-68.	0.7	8
74	Nonbacterial thrombotic endocarditis in autologous bone marrow transplantation. <i>American Journal of Medicine</i> , 1988, 85, 742-744.	0.6	7
75	Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma. <i>Cancer Medicine</i> , 2021, 10, 7585-7592.	1.3	7
76	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. <i>Blood Advances</i> , 2017, 1, 1047-1055.	2.5	6
77	Mononuclear cell collection for extracorporeal photopheresis by using the <i>offâ€line</i> system: A comparative study between COBE Spectra and Spectra Optia devices. <i>Journal of Clinical Apheresis</i> , 2019, 34, 359-366.	0.7	6
78	Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 751-755.	0.5	6
79	Antithymocyte globulin therapy for steroidâ€resistant acute graft versus host disease. <i>American Journal of Hematology</i> , 2008, 83, 824-825.	2.0	5
80	Mesenteric inflammatory veno-occlusive disease (MIVOD) after allogeneic peripheral blood stem cell transplantation (PBSCT). <i>Bone Marrow Transplantation</i> , 2008, 41, 311-313.	1.3	5
81	Recomendaciones de GESIDA/PETHEMA sobre el diagnÃ³stico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana. <i>Medicina CLÃnica</i> , 2018, 151, 39.e1-39.e17.	0.3	5
82	Clinical utility of targeted nextâ€generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition. <i>Molecular Oncology</i> , 2021, 15, 2273-2284.	2.1	5
83	Achievement of early complete donor chimerism in CD25+ activated leukocytes is a strong predictor of the development of graft-versus-host-disease after stem cell transplantation. <i>Experimental Hematology</i> , 2015, 43, 4-13.e1.	0.2	4
84	Wilms Tumor 1 gene expression levels improve risk stratification in <i>scp</i> AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. <i>British Journal of Haematology</i> , 2018, 181, 542-546.	1.2	4
85	Infectious Complications and Mortality after Autologous Stem Cell Transplantation for Lymphomas: A Comparison Between HIV-Infected and HIV-Negative Patients. <i>Blood</i> , 2016, 128, 2258-2258.	0.6	4
86	Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 817-823.	1.3	4
87	Restriction endonuclease in situ digestion (REISD) and fluorescence in situ hybridization (FISH) as complementary methods to analyze chimerism and residual disease after bone marrow transplantation. <i>Cancer Genetics and Cytogenetics</i> , 1996, 89, 141-145.	1.0	3
88	Dynamics of <i>Sau</i> 3A in situ digestion of human chromosomes analyzed with computerized imaging. <i>Genome</i> , 1997, 40, 123-126.	0.9	3
89	<i>Sau</i> 3A in situ digestion of human chromosome 3 pericentromeric heterochromatin. I. Differential digestion of \pm -satellite and satellite 1 DNA sequences. <i>Genome</i> , 2001, 44, 120-127.	0.9	3
90	Transient hemolysis due to antiâ€D and antiâ€A 1 produced by engrafted donor's lymphocytes after allogeneic unmanipulated haploidentical hematopoietic stem cell transplantation. <i>Transfusion</i> , 2017, 57, 2355-2358.	0.8	3

#	ARTICLE	IF	CITATIONS
91	Inonotosis in Patient with Hematologic Malignancy. <i>Emerging Infectious Diseases</i> , 2018, 24, 180-182.	2.0	3
92	Application of the French <sc>TMA</sc> Reference Center Score and the mortality in <sc>TTP Score</sc> in de novo and relapsed episodes of acquired <sc>thrombotic thrombocytopenic purpura</sc> at a tertiary care facility in Spain. <i>Journal of Clinical Apheresis</i> , 2021, 36, 420-428.	0.7	3
93	Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party. <i>Blood</i> , 2016, 128, 2257-2257.	0.6	3
94	Immune Reconstitution Impact on Overall Survival after Hematopoietic Haploidentical Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 5779-5779.	0.6	3
95	Methotrexate-Induced Subacute Neurotoxicity Surrounding an Ommaya Reservoir in a Patient with Lymphoma. <i>American Journal of Case Reports</i> , 2019, 20, 1002-1005.	0.3	3
96	A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. <i>Clinical and Translational Oncology</i> , 2022, 24, 968-980.	1.2	3
97	Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms. <i>Annals of Hematology</i> , 2022, 101, 1567-1576.	0.8	3
98	Post-Transplant Lymphoproliferative Disorder Mimicking a Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1203-1205.	2.0	2
99	Essential thrombocythemia in patients with platelet counts below $600 \times 10^9/L$: Applicability of the 2008 World Health Organization diagnostic criteria revision proposal. <i>American Journal of Hematology</i> , 2009, 84, 452-454.	2.0	2
100	GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 39.e1-39.e17.	0.1	2
101	Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation. <i>Chemotherapy</i> , 2019, 64, 57-61.	0.8	2
102	Autologous stem cell transplantation for lymphoma in HIV+ patients: higher rate of infections compared with non-HIV lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1716-1725.	1.3	2
103	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1047-1055.	1.3	2
104	Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations. <i>Cancers</i> , 2021, 13, 3001.	1.7	2
105	<i>Sau</i>3A in situ digestion of human chromosome 3 pericentromeric heterochromatin. I. Differential digestion of α -satellite and satellite 1 DNA sequences. <i>Genome</i> , 2001, 44, 120-127.	0.9	2
106	Cytokine Release Syndrome after Allogeneic Stem Cell Transplantation with Post Transplant Cyclophosphamide. <i>Blood</i> , 2018, 132, 3367-3367.	0.6	2
107	Myeloablative Conditioning Haploidentical Stem Cell Transplantation (MAC-HAPLO) with Post-Transplant Cyclophosphamide (PTCy) As GvHD Prophylaxis in High Risk Leukemias/Myelodysplastic Syndromes (MDS): Geth Experience. <i>Blood</i> , 2016, 128, 4690-4690.	0.6	2
108	Single Cord Blood Transplantation Combined With An HLA Mismatched Third Party Donor For High-Risk Hematological Patients With HIV Infection. <i>Blood</i> , 2013, 122, 3401-3401.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Clinical grade production of $IL-15$ stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. <i>Transfusion</i> , 2022, 62, 374-385.	0.8	2
110	Aplastic anaemia and cyanamide. <i>European Journal of Haematology</i> , 1992, 48, 179.	1.1	2
111	Sequential fluorescence in situ hybridization for the quantification of minimal residual disease in recipient cells after sex-mismatched allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2002, 118, 349-349.	1.2	1
112	Heterogeneous loss of the Y chromosome in leukocyte lineages of donor origin after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 463-465.	1.3	1
113	Exome sequencing reveals heterogeneous clonal dynamics in donor cell myeloid neoplasms after stem cell transplantation. <i>Haematologica</i> , 2020, 105, 2655-2658.	1.7	1
114	Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis. <i>Blood</i> , 2019, 134, 3285-3285.	0.6	1
115	Genetic biomarkers identify a subgroup of high-risk patients within low-risk $NPM1$ -mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1178-1186.	0.6	1
116	Restriction endonuclease in situ digestion (REISD): a novel quantitative sex-independent method to analyze chimerism after bone marrow transplantation. <i>Experimental Hematology</i> , 1996, 24, 1333-9.	0.2	1
117	Significance in acute myeloid leukemia (AML) of $bcl-2$ protein expression. <i>Haematologica</i> , 1997, 82, 729-30.	1.7	1
118	Plasma exchange as an effective salvage therapy in AZD1222 vaccine-induced thrombotic thrombocytopenia: a case report.. <i>Blood Transfusion</i> , 2021, , .	0.3	1
119	Chimerism Quantification after Sex-Matched BMT. <i>Cancer Genetics and Cytogenetics</i> , 1999, 113, 152-155.	1.0	0
120	A PCR product derived from female DNA with regional localization on the Y chromosome. <i>Genome</i> , 2000, 43, 580-583.	0.9	0
121	Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Htransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2020, 136, 26-27.	0.6	0